- Home
- GNL vs KROS Comparison
GNL vs KROS Comparison
Compare GNL & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNL
- KROS
- Stock Information
- Founded
- GNL 2011
- KROS 2015
- Country
- GNL United States
- KROS United States
- Employees
- GNL N/A
- KROS N/A
- Industry
- GNL Real Estate Investment Trusts
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- GNL Real Estate
- KROS Health Care
- Exchange
- GNL Nasdaq
- KROS Nasdaq
- Market Cap
- GNL 1.6B
- KROS 1.8B
- IPO Year
- GNL N/A
- KROS 2020
- Fundamental
- Price
- GNL $7.18
- KROS $17.03
- Analyst Decision
- GNL Buy
- KROS Buy
- Analyst Count
- GNL 5
- KROS 11
- Target Price
- GNL $9.50
- KROS $78.33
- AVG Volume (30 Days)
- GNL 1.6M
- KROS 1.8M
- Earning Date
- GNL 11-06-2024
- KROS 11-06-2024
- Dividend Yield
- GNL 15.38%
- KROS N/A
- EPS Growth
- GNL N/A
- KROS N/A
- EPS
- GNL N/A
- KROS N/A
- Revenue
- GNL $812,621,000.00
- KROS $651,000.00
- Revenue This Year
- GNL N/A
- KROS $224.66
- Revenue Next Year
- GNL N/A
- KROS N/A
- P/E Ratio
- GNL N/A
- KROS N/A
- Revenue Growth
- GNL 102.00
- KROS 8037.50
- 52 Week Low
- GNL $6.52
- KROS $15.67
- 52 Week High
- GNL $10.19
- KROS $73.00
- Technical
- Relative Strength Index (RSI)
- GNL 40.83
- KROS 22.60
- Support Level
- GNL $7.00
- KROS $16.31
- Resistance Level
- GNL $7.42
- KROS $21.05
- Average True Range (ATR)
- GNL 0.18
- KROS 3.29
- MACD
- GNL 0.01
- KROS -4.56
- Stochastic Oscillator
- GNL 27.38
- KROS 2.40
About GNL Global Net Lease Inc.
Global Net Lease Inc is a real estate investment trust that manages a globally diversified portfolio of commercial real estate properties. The company is engaged in the ownership, management, operating, lease, acquisition, investment, and sale of the portfolio assets. Its segments include Industrial & Distribution; Multi-Tenant Retail; Single-Tenant Retail ; and office. The company derives maximum revenue from industrial and distribution segment. The company geographically operates in Unites States, United Kingdom, Canada and Europe.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.